Partnering
Ethris’ goal is to become the leader in inhaled mRNA therapeutics and next-generation mRNA vaccines.
Partnering Strategy
Ethris is actively seeking to forge strategic partnerships and licensing arrangements with companies, mid and large size, that share our vision of advancing the development of innovative mRNA-based vaccines and therapies. Of interest are:
- Out-licensing of our asthma program ETH47 or other pipeline assets
- Product-development partnerships based on Ethris' proprietary technology platform
- Technology licensing of our proprietary stabilizer and SNaP LNP technology
